Preeclampsia Market Size, Share & Trends Analysis Report By Test Type (Blood Test, Urinalysis), By Application Universal Screening, Targeted Testing), By End Use (Hospitals, Diagnostic Centers), By Region, And Segment Forecasts, 2025 - 2033

Preeclampsia Market Summary

The global preeclampsia market size was valued at USD 1.25 billion in 2024 and is expected to reach USD 2.73 billion by 2033, growing at a CAGR of 9.12% from 2025 to 2033. The market is driven by rising incidences of the preeclampsia and the rising demand for early and accurate diagnostic tests to predict and manage risks before symptoms grow.

Globally, there are near about 140 million births annually; in the U.S. alone, about 3.7 million births per year, of which up to 30 % of pregnancies are affected by complications (including preterm birth, preeclampsia, restricted growth, etc.). In April 2025, Mirvie highlighted that its simple blood test can predict preeclampsia risk in pregnancy as early as 17.5 to 22 weeks-helping clinicians stratify patients and intervene sooner. Preeclampsia is a hypertensive disorder of pregnancy that affects roughly 2 % to 8 % of pregnancies worldwide. It typically presents after 20 weeks of gestation, and is diagnosed by elevated blood pressure and signs of organ dysfunction such as proteinuria. If undetected or unmanaged, the condition can progress to eclampsia (seizures), HELLP syndrome, placental abruption, or other severe complications. Each year, preeclampsia is estimated to be responsible for about 46,000 maternal deaths and 500,000 fetal or newborn deaths globally. Because it contributes significantly to maternal and perinatal morbidity, there is strong demand for better preventive, diagnostic, and management tools.

Preeclampsia is a serious blood pressure condition in the U.S. that affects about 1 in 12 to 1 in 25 pregnancies and is on the rise. After 20 weeks of pregnancy, high blood pressure and indicators of organ damage, such as protein in the urine, which suggests kidney damage, are necessary for the diagnosis. A history of preeclampsia, pre-existing chronic diabetes or hypertension, and first-time pregnancy are risk factors.

In the recent year’s companies such as PerkinElmer added DELFIA Xpress sFlt-1 kit to its CE-IVD pre-eclampsia product offerings. The Thermo Fisher BRAHMS biomarker assays (sFlt-1 / PlGF) are now marketed for preeclampsia management in labs, offering precise risk calculations. As new molecular tests, such as cell-free RNA assays (Mirvie) or predictive risk scores, mature and get regulatory approval, they will broaden the market’s reach into earlier prenatal screening. The global market’s growth is further supported by rising maternal health focus, growing awareness in emerging economies, and increased investment in women’s health technologies.

Adoption is uneven, though. Despite their great need, advanced tests are not widely adopted in low-resource settings due to a lack of infrastructure for biomarker assays, financial limitations, and gaps in prenatal care. The WHO notes that even with guidelines, implementation lags and magnesium sulfate is still underutilized in many low-resource settings. Furthermore, in many areas, market penetration for novel diagnostics is slowed by regulatory and reimbursement barriers. However, these obstacles might lessen as costs come down and test formats (like point-of-care or home sampling) get easier.

Global Preeclampsia Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global preeclampsia market based on test type, application, end use, and region:

• Test Type Outlook (USD Million; 2021 - 2033)
• Blood Tests
• Urinalysis
• Application Outlook (USD Million; 2021 - 2033)
• Universal Screening
• Targeted Testing
• Monitoring & Recurrence Surveillance
• End Use Outlook (USD Million; 2021 - 2033)
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others
• Regional Outlook (USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more